Aav-based gene therapy for glaucoma
AssigneeThe Provost, Fellows, Scholars and Other Members of Board of Trinity College Dublin
InventorsMatthew Campbell, Peter Humphries, Jeffrey O'Callaghan
Life of this patent
Estimating the term…
Abstract
The disclosure provides compositions and methods useful for treating glaucoma. In particular, the invention provides an adeno-associated viral (AAV)-mediated gene therapy for glaucoma in which transduced cells of the eye secrete a therapeutic protein (for example, a matrix metalloproteinase) resulting in remodeling of the extracellular matrix of the trabecular meshwork of said eye.
Claims27
A recombinant AAV (rAAV) vector comprising a polynucleotide sequence encoding matrix metalloproteinase 3 (MMP-3).
3-5. (canceled)
(canceled)
11-12. (canceled)
A method of treating a vision disorder in a subject suffering from the vision disorder, comprising administering to an eye of the subject a therapeutically effective amount of a recombinant AAV (rAAV) comprising a polynucleotide sequence encoding matrix metalloproteinase 3 (MMP-3).
19-20. (canceled)
23-27. (canceled)
A method of treating a vision disorder in a mammal, comprising injecting a therapeutic composition comprising a rAAV vector into the anterior chamber of said mammal's eye,
- wherein the rAAV vector transduces cells in the anterior chamber;
- wherein the transduced cells secrete a therapeutic protein;
- wherein the therapeutic protein modifies the extracellular matrix of the trabecular meshwork of said mammal's eye;
- wherein said method treats said vision disorder in said mammal.
(canceled)
32-36. (canceled)
38-41. (canceled)
Dependencies are inferred from the claim text.